Medifast, Inc. (MED) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Medifast, Inc. operates the OPTA VIA lifestyle solution, a habit-based, coach-guided weight loss program. The company is currently undergoing a business transformation to integrate medically supported weight loss solutions, including GLP-1 medications, through a strategic collaboration with LifeMD, Inc. The company reported a net loss for the quarter, driven by significant declines in revenue and active coaches, partially offset by cost management initiatives.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $168.6 million | $296.2 million | $343.3 million | $645.2 million |
| Gross Profit | $123.4 million | $210.7 million | $250.7 million | $457.1 million |
| Gross Margin | 73.2% | 71.1% | 73.0% | 70.9% |
| Operating Income (Loss) | ($7.9 million) | $38.7 million | $0.06 million | $92.2 million |
| Net Income (Loss) | ($8.2 million) | $30.3 million | $0.2 million | $70.2 million |
| Diluted EPS | ($0.75) | $2.77 | $0.01 | $6.43 |
| Cash & Equivalents | $108.0 million | $147.4 million (YTD 2023 end) | Investment Securities: $55.5 million | |
| Working Capital | $149.1 million | $131.7 million (Dec 31, 2023) | ||
| Debt | $0 (No borrowings) | Credit Facility: $225M available, $0 utilized |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 43.1% year-over-year in Q2 and 46.8% year-over-year for the six months ended June 30, 2024. This was primarily driven by a 36.2% decrease in active earning OPTA VIA Coaches (down to 33,900) and a 10.9% decrease in revenue per coach.
- Profitability Shift: The company swung from an operating profit of $38.7 million in Q2 2023 to an operating loss of $7.9 million in Q2 2024. YTD operating income collapsed from $92.2 million to $0.06 million.
- SG&A Expenses: Selling, general, and administrative expenses decreased 23.7% to $131.3 million, largely due to reduced coach compensation. However, as a percentage of revenue, SG&A increased to 77.9% from 58.1% due to the loss of leverage on fixed costs.
- Supply Chain Optimization: The company incurred $12.5 million in one-time supply chain optimization charges in Q2 2024, including $9.2 million in accelerated depreciation and $2.5 million in impairment losses, following the closure of its Maryland Distribution Center.
- Investment Losses: Unrealized losses on the LifeMD equity investment totaled $4.2 million in Q2 2024, impacting other income/expense.
Guidance, Outlook, and Risks
- Strategic Transformation: Management is investing approximately $25 million in company-led marketing in 2024 to broaden customer acquisition channels beyond the traditional coach model. This includes a national marketing campaign launched in May 2024.
- LifeMD Collaboration: The partnership aims to integrate GLP-1 medication access with OPTA VIA's lifestyle program. Milestone payments totaling $10 million have been made to LifeMD, with amortization impacting SG&A.
- Outlook: Management anticipates continued pressure on customer acquisition and a short-term decline in active coaches. They expect the new marketing and medical integration initiatives to lay the foundation for improved performance in 2025 and beyond.
- Risks: Key risks include the competitive threat from GLP-1 medications, macroeconomic inflation affecting consumer spending, and the success of the new marketing initiatives in reversing the decline in coach activity.
- Dividends: No cash dividends were declared in Q2 2024, a change from the $1.65 per share dividend declared in Q2 2023.
Investor Verification Checklist
- Verify the trajectory of active earning OPTA VIA Coaches and whether the new marketing spend is stabilizing this metric.
- Assess the impact of the LifeMD collaboration on future revenue streams and the amortization schedule of the $10 million milestone payments.
- Review the supply chain optimization benefits to ensure the $12.5 million one-time charge translates to sustained cost savings.
- Monitor the cash burn rate relative to the $25 million marketing investment and the cessation of dividends.
- Confirm the valuation and liquidity status of the LifeMD equity investment ($8.4 million fair value as of June 30, 2024) given the recent unrealized losses.